Prima BioMed updates CVac development program
Clinical trial focus on second-remission ovarian cancer patient
Prima BioMed Ltd provided significant updates to its CVac™ clinical development program.
Prima previously reported all progression-free survival data from its CAN-003 protocol, a 63-patient phase 2 trial of CVac for the treatment of epithelial ovarian cancer in remission after standard first-or second-line treatment. In 20 patients in second remission on the CAN-003 trial, CVac conferred approximately a 50% increase in progression free survival as compared to observation only (7.69 months versus 5.14 months; HR=0.41; p=0.09).
Prima will move forward with a 210-patient phase 2, multicentre, randomized, and controlled trial of CVac for the maintenance treatment of platinum sensitive, epithelial ovarian cancer patients who achieve remission after second-line platinum-based treatment. This trial will be conducted as an amendment to the CAN-004 protocol. The primary endpoint for this study will be Overall Survival (OS); secondary endpoints include progression-free survival (PFS), adverse events, and immune monitoring. Prima will also move forward with a 40-patientpilot, multicentre, single-arm trial of CVac for the maintenance treatment of resected pancreatic cancer patients. This trial will assess OS, PFS, adverse events, and immune monitoring.
Matthew Lehman, Prima’s CEO: “Though based on a small cohort of 20 patients, we are pleased to see a strong clinical signal in the second-remission ovarian cancer patient population from the CAN-003 trial. Ovarian cancer has proven a very difficult cancer to treat. We are excited to move forward with our 210-patient trial of this second-remission patient population. If we are able to confirm similar results as the CAN-003 trial, we would have compelling proof of clinical concept for CVac to treat ovarian cancer.”
The Company further advised that it will not enrol additional first-remission ovarian cancer patients onto the CAN-004 trial and that it will not commence trials of triple-negative breast and colorectal cancers. There are currently 76 randomized patients in first-remission on the CAN-004 trial; these patients will be allowed to continue on the protocol and will be analysed separately to the second-remission cohort.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.